Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?

RETRACTED: Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial

“…This hypoestrogenic state releases the hypothalamic-pituitary axis from estrogenic negative feedback, which in turn increases FSH secretion and the development of ovarian follicles. Since the early reports by Mitwally and Casper (13), many studies have weighed aromatase inhibitors as ovulatory agents in various indications with contradictory results (14)(15)(16)(17). Recently, Polyzos et al (15), in a meta-analysis, seriously questioned the value of letrozole versus CC in ovulation induction in patients with polycystic ovary syndrome.…”

Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction

“…Unlike CC, aromatase inhibitors do not antagonize the estrogen receptor in the endometrium, a wellknown adverse affect of CC (7,20,21). This lack of antagonism may contribute to increased pregnancy and live birth rates (22). Moreover, the present study suggests that combined therapy of letrozole and luteal-phase P may improve pregnancy rates compared with letrozole alone.…”

Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women

“…Of note, aromatase inhibitors have been proposed to treat PCOS patients, since they may stimulate pituitary secretion of FSH by reducing circulating estrogen levels (Polyzos et al 2008, Misso et al 2012, Pavone & Bulun 2013, Legro et al 2014. However, clinical trials of aromatase inhibitors for PCOS yield controversial results regarding pregnancy rates (Badawy et al 2009, Kar 2012, Roy et al 2012).…”